Skip to main content
BIOVIE INC. logo

BIOVIE INC. — Investor Relations & Filings

Ticker · BIVI ISIN · US09074F4054 US Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2020-09-18 Capital/Financing Update
Country US United States of America
Listing US BIVI

About BIOVIE INC.

https://www.bioviepharma.com/

BioVie Inc. is a clinical-stage biopharmaceutical company that develops drug therapies for chronic debilitating conditions. The company's pipeline focuses on neurological and neurodegenerative disorders as well as advanced liver disease. Its lead drug candidate, bezisterim, is being studied for Alzheimer's disease based on the hypothesis that modulating inflammation and enhancing insulin sensitivity in the brain can improve cognitive function and provide neuroprotection. Other areas of focus include Parkinson's disease, ascites (a common complication of advanced liver cirrhosis), and Long COVID. The company also conducts research into epigenetic mechanisms, such as DNA methylation, to understand gene expression regulation.

Recent filings

Filing Released Lang Actions
424B4
Capital/Financing Update Classification · 100% confidence The document is a prospectus filed pursuant to Rule 424(b)(4) related to a public offering of common stock by BioVie Inc. It details the number of shares offered, pricing, underwriting discounts, use of proceeds, risk factors, business description, management discussion, and other information typical of a securities offering document. This is not a financial report, earnings release, or management discussion report, but a capital raising document intended to inform potential investors about the offering and the company. Therefore, it fits the definition of a Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, underwriting details, and risk disclosures consistent with a prospectus for a public offering.
2020-09-18 English
Regulatory Filings 2020
Regulatory Filings
2020-09-18 English
S-1MEF
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes details about the securities to be registered, offering price, registration fee, and signatures of company officers. This type of filing is related to capital raising activities and is not an annual report, earnings release, or other financial report. It is a primary registration document for an initial or additional public offering, which fits the category of Capital/Financing Update filings. The document length is 9701 characters, which is substantive and contains detailed registration information, not just an announcement or a brief notice. Therefore, the correct classification is Capital/Financing Update (CAP).
2020-09-18 English
Regulatory Filings 2020
Regulatory Filings
2020-09-17 English
Capital/Financing Update 2020
Capital/Financing Update Classification · 95% confidence The document is a letter from ThinkEquity, a financial management division, addressed to the U.S. Securities and Exchange Commission regarding a Registration Statement on Form S-1. It specifically mentions concurrence in the acceleration request for the effective date of the registration statement. The content is related to the process of securities registration and offering, not a financial report, earnings release, or management discussion. The document is short (1241 characters) and is a formal correspondence related to a capital raising process. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2020-09-16 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a letter from BioVie Inc. to the SEC requesting acceleration of the effectiveness of registration statements on Form S-1 and Form 8-A. It is a correspondence related to securities registration and does not contain financial statements, management discussion, or detailed report content. The document is short (983 characters) and is a regulatory communication rather than a report or announcement of financial results. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2020-09-16 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.